Literature DB >> 30510852

68Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis.

Christos Sachpekidis1,2, Leyun Pan1, Boris A Hadaschik3,4, Klaus Kopka5,6, Uwe Haberkorn1,2, Antonia Dimitrakopoulou-Strauss1.   

Abstract

68Ga-PSMA-11 PET/CT performed 60 min post tracer injection (p.i.) can underestimate prostate cancer (PC) local recurrence, due to high 68Ga-PSMA-11 urinary bladder accumulation. Aim of this analysis is to evaluate the complementary role of early dynamic and parametric PET imaging in patients with PC local recurrence. Sixteen patients with PC biochemical relapse attributed to local recurrence underwent dynamic 68Ga-PSMA-11 PET/CT scanning of the pelvis and whole-body PET/CT. Data analysis was based on visual analysis of the PET/CT scans, SUV calculations, quantitative analysis based on two-tissue compartment and Patlak models as well as parametric imaging based on Patlak analysis. 12/16 patients were PSMA-positive in the static 68Ga-PSMA-11 PET/CT scans (60 min p.i.). All 12 lesions corresponding to PC local recurrence were detected in the early dynamic images at a median time of 4.5 min p.i. (range = 1.5-11.5 min). Moreover, early dynamic PET imaging could detect local recurrence in 1/4 static PET/CT-negative patients. Tracer accumulation in the urinary bladder began at a median time of 10 min (range = 6.0-17.5 min). All PC local recurrences visible on late static PET/CT and the local recurrence, which was positive only in early dynamic but not in late PET images, could be delineated on Patlak images. The present findings indicate that early dynamic 68Ga-PSMA-11 PET/CT scan of the pelvis up to 12 min p.i. as well as Patlak analysis, performed in addition to the conventional PET/CT acquired at 60 min p.i., seem a practical approach to increase the detection rate of PC local recurrence.

Entities:  

Keywords:  68Ga-PSMA-11 PET/CT; Patlak analysis; Prostate cancer local recurrence; early dynamic PET imaging

Year:  2018        PMID: 30510852      PMCID: PMC6261880     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  25 in total

Review 1.  Prostate cancer: multiparametric MR imaging for detection, localization, and staging.

Authors:  Caroline M A Hoeks; Jelle O Barentsz; Thomas Hambrock; Derya Yakar; Diederik M Somford; Stijn W T P J Heijmink; Tom W J Scheenen; Pieter C Vos; Henkjan Huisman; Inge M van Oort; J Alfred Witjes; Arend Heerschap; Jurgen J Fütterer
Journal:  Radiology       Date:  2011-10       Impact factor: 11.105

2.  Requirements and implementation of a flexible kinetic modeling tool.

Authors:  C Burger; A Buck
Journal:  J Nucl Med       Date:  1997-11       Impact factor: 10.057

3.  Parametric Net Influx Rate Images of 68Ga-DOTATOC and 68Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast.

Authors:  Ezgi Ilan; Mattias Sandström; Irina Velikyan; Anders Sundin; Barbro Eriksson; Mark Lubberink
Journal:  J Nucl Med       Date:  2016-10-27       Impact factor: 10.057

4.  68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.

Authors:  Matthias Eder; Martin Schäfer; Ulrike Bauder-Wüst; William-Edmund Hull; Carmen Wängler; Walter Mier; Uwe Haberkorn; Michael Eisenhut
Journal:  Bioconjug Chem       Date:  2012-03-13       Impact factor: 4.774

Review 5.  Radionuclide and hybrid imaging of recurrent prostate cancer.

Authors:  Ambros J Beer; Matthias Eiber; Michael Souvatzoglou; Markus Schwaiger; Bernd Joachim Krause
Journal:  Lancet Oncol       Date:  2010-07-06       Impact factor: 41.316

6.  The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer.

Authors:  Ali Afshar-Oromieh; Lars Peter Sattler; Walter Mier; Boris A Hadaschik; Jürgen Debus; Tim Holland-Letz; Klaus Kopka; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2017-01-06       Impact factor: 10.057

7.  68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer.

Authors:  Christos Sachpekidis; P Bäumer; K Kopka; B A Hadaschik; M Hohenfellner; A Kopp-Schneider; U Haberkorn; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-23       Impact factor: 9.236

8.  Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI.

Authors:  Martin T Freitag; Jan P Radtke; Ali Afshar-Oromieh; Matthias C Roethke; Boris A Hadaschik; Martin Gleave; David Bonekamp; Klaus Kopka; Matthias Eder; Thorsten Heusser; Marc Kachelriess; Kathrin Wieczorek; Christos Sachpekidis; Paul Flechsig; Frederik Giesel; Markus Hohenfellner; Uwe Haberkorn; Heinz-Peter Schlemmer; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-17       Impact factor: 9.236

9.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations.

Authors:  C S Patlak; R G Blasberg
Journal:  J Cereb Blood Flow Metab       Date:  1985-12       Impact factor: 6.200

10.  Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

Authors:  Ali Afshar-Oromieh; Tim Holland-Letz; Frederik L Giesel; Clemens Kratochwil; Walter Mier; Sabine Haufe; Nils Debus; Matthias Eder; Michael Eisenhut; Martin Schäfer; Oliver Neels; Markus Hohenfellner; Klaus Kopka; Hans-Ulrich Kauczor; Jürgen Debus; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-12       Impact factor: 9.236

View more
  7 in total

1.  18F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer.

Authors:  Christos Sachpekidis; A Afshar-Oromieh; K Kopka; D S Strauss; L Pan; U Haberkorn; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-14       Impact factor: 9.236

2.  Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic 18F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group.

Authors:  Christos Sachpekidis; Ioannis Karampinis; Jens Jakob; Bernd Kasper; Kai Nowak; Lothar Pilz; Ulrike Attenberger; Timo Gaiser; Hans-Günter Derigs; Matthias Schwarzbach; Peter Hohenberger; Antonia Dimitrakopoulou-Strauss; Ulrich Ronellenfitsch
Journal:  Cancers (Basel)       Date:  2019-06-08       Impact factor: 6.639

3.  Early differences in dynamic uptake of 68Ga-PSMA-11 in primary prostate cancer: A test-retest study.

Authors:  J Olde Heuvel; B J de Wit-van der Veen; M Sinaasappel; C H Slump; M P M Stokkel
Journal:  PLoS One       Date:  2021-02-02       Impact factor: 3.240

Review 4.  Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives.

Authors:  Antonia Dimitrakopoulou-Strauss; Leyun Pan; Christos Sachpekidis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-05-19       Impact factor: 9.236

5.  Is there a diagnostic benefit of late-phase abdomino-pelvic PET/CT after urination as part of whole-body 68 Ga-PSMA-11 PET/CT for restaging patients with biochemical recurrence of prostate cancer after radical prostatectomy?

Authors:  Janna Morawitz; Julian Kirchner; Johannes Hertelendy; Christina Loberg; Lars Schimmöller; Mardjan Dabir; Lena Häberle; Eduards Mamlins; Christina Antke; Christian Arsov; Gerald Antoch; Lino M Sawicki
Journal:  EJNMMI Res       Date:  2022-03-04       Impact factor: 3.138

6.  Hybrid imaging with [68Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer.

Authors:  P A Glemser; L T Rotkopf; C H Ziener; B Beuthien-Baumann; V Weru; A Kopp-Schneider; H P Schlemmer; A Dimitrakopoulou-Strauss; C Sachpekidis
Journal:  Cancer Imaging       Date:  2022-09-22       Impact factor: 5.605

7.  Pharmacokinetic studies of [68 Ga]Ga-PSMA-11 in patients with biochemical recurrence of prostate cancer: detection, differences in temporal distribution and kinetic modelling by tissue type.

Authors:  Dimitrios S Strauss; C Sachpekidis; K Kopka; L Pan; U Haberkorn; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-10       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.